novo nordisk semaglutide shortage US FDA says two more doses of Nordisk's weight-loss drug now available FDA declares Wegovy® and Ozempic®

This resulted in a significantly greater improvement in the TyG index at week 12 in the high GLP-1 group compared to the low GLP-1 group [between-group difference -0.19 (95% CI -0.39, -0.01)] ( Table 4 )

Why it pairs with BPC-157: BPC-157 delivers localized repair to a specific joint

In the comparison between Wegovy and Zepbound, Zepbound did have more weight loss and, interestingly, fewer side effects, Ali said

Changes in patients' taste acuity after Roux-en-Y gastric bypass for clinically severe obesity

The FDA flagged marketing claims suggesting that compounded GLP-1s shared the same safety and efficacy profiles as their branded counterparts, noting that such labeling can mislead consumers and violate the Food, Drug, and Cosmetic Act

Eli Lillys comparable drugs generated $8.6B (Mounjaro $5.2B, Zepbound $3.4B)